Table I.
Patient characteristics.
| Patient | Age | Sex | Disease | Response at time of transplant |
Type of transplant |
CMV status recipient/donor |
Stem cell source |
Donor sex/age | Patient/donor ABO type |
Conditioning* regimen |
aGVHD prophylaxis |
Disease response post transplant |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 38 | M | MDS with t (3;12) | Persistent disease | Double cord | IgG+IgM-/Neg | Cord | Both F | O/B O/O |
MA Flu/Cy/TBI |
Tacro/MMF | CR |
| 2 | 62 | M | Pre B ALL Ph+ (transformed from CML) | CR1 | Matched Sibling | IgG +IgM-for both | PB | M/70yrs | A/O | RIC Flu/Bu |
Tacro/MTX | Morphological CR |
| 3 | 48 | F | AML primary induction refractory | Minimal residual disease | Double Cord | Recipient neg | Cord | M F |
A/A A/O |
MA Flu/Cy/TBI |
Tacro/MMF | CR |
| 4 | 50 | F | follicular lymphoma | PR2 | Double Cord | Recipient neg | Cord | M F |
A/O A/O |
RIC Flu/Cy/TBI |
Tacro/MMF | CR |
| 5 | 41 | M | AML Inv 16 | CR2 | 9/10 DQ mismatch, unrelated | Neg/IgG+IgM- | Bone marrow | M/32yrs | A/O | MA Cy/TBI |
Tacro/MMF/RGI 2001 | CR |
| 6 | 42 | M | CLL del 17P and del 11q | PR | Matched Sibling | Neg/IgG+IgM- | PB | F age unknown | Unknown. Allo HSCT done outside hospital | MA TBI |
CSA/MMF | CR |
| 7 | 49 | F | MDS with monosomy 7 | Persistent disease | Cord failed Haploidentical |
Recipient neg Neg/ |
Cord PB |
F M/47 |
O/O O/O |
MA Flu/Mel/Cy MA Flu/Cy/TBI |
Tacro/MMF Tacro/MMF |
CR |
| 8 | 61 | M | CLL del 17P | PR | Matched unrelated | Neg/IgG+IgM- | PB | M/28yrs | O/O | RIC Bu/Flu/ATG |
Tacro/MTX | CR |
| 9 | 25 | F | B cell ALL | CR1 | Double Cord | Recipient neg | Cord | M M |
O/O O/B |
MA Flu/Cy/TBI |
Tacro/MMF | CR |
GVHD, graft-versus-host disease; CMV, cytomegalovirus; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; TBI, total body irradiation; MMF, mycophenolate mofetil; PB, peripheral blood; ATG, antithymocyte globulin; Tacro, tacrolimus; MTX, methotrexate; CSA, cyclosporine; MA, myeloablative; RIC, reduce intensity conditioning, Flu, fludarabine; Bu, Busulfan; Cy, cyclophosphamide; CR, complete response; PR, partial response
Dosing: all by intravenous infusion where indicated. MA Flu/Cy/TBI: Flu 25 mg/m2/day × 3 doses day −8 to−6, Cy 60 mg/kg/day × 2 doses day −7 to −6, TBI 12 Gy (in divided doses given twice a day over 4 days, day −4 to−1). Day 0 is day of stem cells infusion. MA Cy/TBI: Cy 60 mg/kg/day × 2 doses day −5 to−4, TBI 12 Gy (in divided doses given twice a day over 3 days, day −3 to −1). MA Flu/Mel/Cy: Flu 30 mg/m2/day × 5 doses days −6 to −2, Mel 140 mg/m2 divided on days −3 and −2, Cy 50 mg/kg/day × 2 doses, day +3 and +4. MA TBI: sequence administration unknown as allo HSCT done at outside hospital. RIC Flu/cy/TBI: Flu 40 mg/m2/day × 5 doses days −6 to −2, Cy 50 mg/kg once day −6, TBI 2 Gy once day −1. RIC Bu/Flu/ATG: Flu 30 mg/m2/day × 5 doses day −7 to −3, Bu 0.8 mg/kg every 6 hours × 8 doses day −4 to −3, ATG 2 mg/kg/day, day −4 to −2.